Comparative Pharmacology
Head-to-head clinical analysis: CLISTIN versus VISTARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLISTIN versus VISTARIL.
CLISTIN vs VISTARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clistin (histamine-1 receptor antagonist) competitively blocks histamine at H1 receptor sites, inhibiting vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
4 mg orally every 4-6 hours as needed; maximum 24 mg/day.
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Primarily renal excretion (approximately 85-90% as unchanged drug and metabolites). Biliary/fecal elimination accounts for the remainder (10-15%).
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Category C
Category C
Antihistamine
Antihistamine